XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (unaudited) - USD ($)
$ in Thousands
Total
Series A
Series B
Series C
IPO
Private Placement
Common Stock
Common Stock
IPO
Common Stock
Private Placement
Additional Paid In Capital
Additional Paid In Capital
IPO
Additional Paid In Capital
Private Placement
Accumulated Deficit
Accumulated Other Comprehensive Gain (Loss)
Beginning Balance at Dec. 31, 2021 $ (121,515)           $ 1     $ 8,615     $ (130,111) $ (20)
Beginning Balance, Shares at Dec. 31, 2021             544,210              
Temporary Equity, Beginning Balance at Dec. 31, 2021   $ 28,894 $ 85,367 $ 119,118                    
Temporary Equity, Beginning balance, shares at Dec. 31, 2021   5,413,272 8,975,585 10,396,707                    
Issuance of common stock, net of transaction costs, value         $ 127,283 $ 9,958   $ 9 $ 1   $ 127,274 $ 9,957    
Issuance of common stock , net of transaction costs, shares               9,487,500 590,318          
Conversion of preferred stock to common stock, value 233,379           $ 25     233,354        
Conversion of preferred stock to common stock, shares             24,785,564              
Temporary Equity, Conversion of stock, value   $ (28,894) $ (85,367) $ (119,118)                    
Temporary Equity, Conversion of stock, shares   (5,413,272) (8,975,585) (10,396,707)                    
Issuance of common stock from vesting of restricted stock, value 107                 107        
Issuance of common stock from vesting of restricted stock, shares             24,889              
Exercise of stock options, value 307                 307        
Exercise of stock options, shares             286,283              
Share-based compensation 4,481                 4,481        
Unrealized gain (loss) on marketable securities (24)                         (24)
Net loss (26,041)                       (26,041)  
Ending Balance at Mar. 31, 2022 227,935           $ 36     384,095     (156,152) (44)
Ending Balance, shares at Mar. 31, 2022             35,718,764              
Beginning Balance at Dec. 31, 2022 204,954           $ 44     523,921     (318,790) (221)
Beginning Balance, Shares at Dec. 31, 2022             44,105,981              
Issuance of common stock in accordance with Gilead Stock Purchase Agreement, shares 115,270           $ 4     115,266        
Issuance of common stock in accordance with Gilead Stock Purchase Agreement, value             3,478,261              
Issuance of common stock from vesting of restricted stock, shares             222,433              
Exercise of stock options, value 374                 374        
Exercise of stock options, shares             34,713              
Share-based compensation 10,156                 10,156        
Unrealized gain (loss) on marketable securities 307                         307
Net loss (27,344)                       (27,344)  
Ending Balance at Mar. 31, 2023 $ 303,717           $ 48     $ 649,717     $ (346,134) $ 86
Ending Balance, shares at Mar. 31, 2023             47,841,388